Top of this page
Skip navigation, go straight to the content

UCB's new development pipeline

Small molecule drug / NCE

Small molecule drug / NCE

Antibody-based drug / NBE

Antibody-based drug / NBE



CNS Indications Phase 1 Phase 2 Phase 3 Filed
Keppra®epilepsy - adjunctive therapy (Japan)
phase 4
Neupro®
advanced Parkinson's disease (U.S.)
phase 4
Neupro®
restless legs syndrome (U.S.)
phase 4
Xyrem®
fibromyalgiaphase 3
brivaracetamepilepsy - adjunctive therapy
phase 3 half
Vimpat®epilepsy - monotherapy (U.S.)
phase 3 half
Vimpat®epilepsy adjunctive therapy 1
phase 2
Vimpat®epilepsy adjunctive therapy PGTC 2
phase 2
UCB 2892central nervous system
phase 1 half
Immunology Indications Phase 1 Phase 2 Phase 3 Filed
Cimzia®ankylosing spondylitisphase 3 half
Cimzia®psoriatic arthritisphase 3 half
Cimzia®juvenile rheumatoid arthritisphase 3 half
Cimzia®rheumatoid arthritis (Japan)phase 3 half
epratuzumabsystemic lupus erythematosusphase 2
CDP7851fracture healingphase 2 half
CDP7851post-menopausal osteoporosisphase 2 half
CDP6038auto-immune diseasesphase 1 half
CDP7657systemic lupus erythematosusphase 1 half
1. Paediatric 2-17 years
2. Primary generalised tonic clonic